Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medic
Rucaparib New Drug Application (NDA) accepted for Priority Review
in the treatment of advanced BRCA-mutant ovarian cancer; PDUFA date
February 23, 2017
Rucaparib MAA submission submitted this week
Clovis commercial and medical affairs organizations preparing for
potential U.S. commercial launch of rucaparib
ARIEL3 pivotal rucaparib maintenance study enrollment completed;
data expected i...
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 31, 2016--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick
Mahaffy, the Company’s President and CEO, will present at the 2016
Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm
MST. The conference is being held at the Phoenician in Scottsdale,
A live webcast of the corporate presentation at the conference will be
accessible through the investor relations se...
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 27, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter
2016 financial results on Thursday, November 3, 2016, after the close of
the U.S. financial markets. Clovis’ senior management will host a
conference call and live audio webcast at 4:30 p.m. ET that day to
discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.